Ritedose

Leading pharmaceutical producer using blow-fill-seal (BFS) technology

Deal Facts

Ritedose is a leading unit-dose sterile Rx and Gx pharmaceutical CDMO in the US using BFS technology, producing ~1.0 billion units annually for the respiratory, ophthalmic, and oral liquid markets. BFS technology is a manufacturing technique where a container is formed, filled, and sealed in a fully automated continuous aseptic process
Manufactures pharmaceutical products for CDMO customers and Ritedose branded generic products (RDP) with an industry-leading quality and compliance track record

BFS injectables exhibit attractive growth rates as pharma companies increasingly adopt cost-efficient and innovative unit-dose packaging for existing and new therapies. Ritedose is very well-positioned to capitalize on these secular market tailwinds
Opportunity to continuously grow high margin core business with a robust pipeline of new products and organically expand into adjacent market segments
Strong platform for international expansion by way of new product approvals and bolt-on acquisitions

AGIC supported management to increase capacity, launch new product lines and leverage Ritedose’s process capabilities and automated infrastructure for operational efficiencies to reinforce its market leader status underpinned by best-in-class production throughput and lowest BFS unit costs
Strategically expanded RDP business with new inhalation and ophthalmic products and supported Ritedose’s expansion into the underserved 503B market, which is estimated at ~$900 million p.a. and benefits from a trend towards increased outsourcing
Helped Ritedose obtain the CFDA approval in cooperation with local distribution partners, paving the way for future growth through new market penetration